This study is for patients with a type of blood cancer called multiple myeloma that has come back or isn’t responding to treatment. It tests two drugs, venetoclax and tocilizumab, to find the best dose and check for side effects. Venetoclax may help stop cancer by blocking a protein called Bcl-2 that cancer cells need to grow. Tocilizumab, a monoclonal antibody, is used to treat side effects from immune therapy and might help by stopping cancer cells from spreading.

• The study lasts for 21-day cycles, and treatment continues as long as it is working and side effects are manageable. After completing the study, patients are followed up for 4 weeks, then every 6 months.
• Participants receive tocilizumab through an IV on certain days, and take venetoclax by mouth for 21 days in each cycle.
• Eligibility includes being 18 or older, having had at least three prior cancer treatments, and having a certain genetic translocation called t(11;14).